South Korea Pharmaceutical Market Outlook – A destination for pharmaceutical brands

South Africa is considered as a fast growing market in the Global Pharmaceutical Industry Landscape. In the year 2010, the country was officially considered as a developed economy. Though there is an economic situation in many emerging economies, the South Korean market has managed to sail through and has shown itself as a good destination for investment.

Latest report on South Korean Pharmaceutical market states that the South Korean market is 10th largest market in the globe. The country has strong local players with formidable portfolios of generic drugs over expensive branded drugs. The domestic drug companies are strongly sticking to the concept of providing inexpensive generic drugs to maintain their strong hold in the market. The growing insurance coverage, ageing population promoting healthcare expenditure in South Korea, and government initiatives that are favouring the development of the industry are some of the major factors that would contribute the growth of the market.

Browse Complete report with TOC:http://www.reportsandintelligence.com/south-korea-pharmaceutical-outlook-2013-market

Multinational companies are taking advantage of prevailing opportunities in the country due to conducive market conditions in the South Korean regions. The free trade agreement signed by the South Korean government with countries such as USA, Europe and India is further making the region a favourite for multinational companies. The aforementioned positive indications has led the investing syndicates to be favourable towards the South Korean market. Transparent government policies and enforcements, and competitive pricing platforms in the private sectors would further add to the growth of the market.

Web Link: http://www.reportsandintelligence.com/

ADHD Therapeutics to 2020: Epidemiology, and market growth

ADHD Therapeutics to 2020: Epidemiology, and market growth

Though there are cases where patents are expiring for the ADHD therapeutics, yet the market is still green about the future of the therapy. Attention deficit hyperactivity disorder (ADHD) has been in news since a decade now, and the publications pertaining to the same have steadily increased.

ADHD in children, is an attention deficit disorder where a child is unable to focus on anything for a long time. This impacts the overall effectiveness of the child and leads to frustration and sense of digestion in the child. Lately, ADHD Symptoms are also found in adults and considered as one of the more common adult psychiatric disorders.

What causes attention deficit disorder?
As it is a case with most mental disorders, it is difficult to trace the exact cause of ADHD disorder. It has nothing to do with parenting and child rearing; therefore, parents should not blame themselves for the situation. Some light can be shed that would allow tracing the symptoms of ADHD and they are genes, nutrition and food, brain injury, and also the environmental conditions.
Changes in the Therapeutics

Over the years, changes in the criteria of diagnosis has reduced the symptom threshold, which was otherwise high, and is also being accepted in clinical settings. The adults who were less privileged earlier are no more limited in treating the case, instead, are now gaining access to better treatment for ADHD condition.

A study states that almost 4.1% of the Adults in the US suffer from ADHD, and out of these cases, almost 41.3% of the cases are found to be server and definitely need treatment. The use of Extended-Release (ER) stimulant drugs have been dominantly used in treating the condition. It has been found that the treatment is almost 70-90% effective in treating the patients suffering from severe conditions.

The simulants used can be potentially be abused in some cases. Non simulants are used in patients who don’t respond well to the treatment due to poor cardiac history or also because of the need for non-simulant medication. Nevertheless, the efficiency of non-simulants are comparatively lower than the simulants.

Browse complete report with TOC:http://www.reportsandintelligence.com/adhd-therapeutics-to-2020-broadened-diagnostic-criteria-and-growing-adult-prevalence-to-drive-growth-despite-patent-expirations-market 

Current developments:

The potential gaps in the treatment are being addressed in the present pipelines. It is forecast that 3 non-simulants are entering the market during the forecast period. SHP465 is also another potential treatment that might bridge the prevailing gaps in the market.
The growing prevalence of ADHD in both children and adults will be the primary motivating factor that would propel the growth of the market, and not the drug approvals. The ever increasing population that is eligible for treatment is the undercurrent for the market growth.
Based on the prevalence of cases of ADHD, it can be safely assumed that this market has a tremendous potential for growth. The forecast states that the market could reach up to $9.4 Billion by 2020.

Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

Critical Care Therapeutics in Major Developed Markets to 2020

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

Browse complete report with TOC: http://www.reportsandintelligence.com/critical-care-therapeutics-in-major-developed-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.

The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Table of Contents:

1 Table of Contents
2 Introduction
3 Therapeutic Landscape
4 Pipeline for Critical Care Market
5 Critical Care Market Forecast to 2020
6 Deals and Strategic Consolidations
7 Critical Care Market to 2020

Web Link: http://www.reportsandintelligence.com/

Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

GBI Research, a leading business intelligence provider, has released its latest research report, "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany".

Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment.

Browse complete report with TOC:
http://goo.gl/iKaQfH 

During the 20132020 forecast period, the GBM market is expected to grow rapidly from $301m to $623m. The market entry of Northwest Biotherapeutics’ DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline.

Scope

The report assesses the current GBM market and forecasts market trends to 2020, analyzing key drivers and barriers.The report includes -
- A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis
- In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
- A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target
- Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate
- Multi-scenario forecast data for the GBM market to 2020, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
- Discussion of the licensing and co-development deals landscape in GBM


Reasons to buy

The report will assist business development and enable marketing executives who wish to strategize their product launches by allowing them to -
- Understand the different levels of GBM therapies for newly diagnosed and recurrent GBM
- Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent
- Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market

Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets

Facial Aesthetics Market to 2020

GBI Research’s report, “Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets” discusses the market, competitive landscape, and trends for two facial aesthetics market segments: Botox and dermal fillers. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Browse complete report with TOC: http://www.reportsandintelligence.com/facial-aesthetics-to-2020-economic-recovery-drives-growth-in-the-us-as-increasing-awareness-fuels-demand-in-developing-market

Scope

- Key geographies: US, Brazil, Germany, Turkey, France, Italy, Spain, Japan, China, India, Columbia and South Korea.

- Information on market size for two facial aesthetics market segments: botox and dermal fillers.

- Annualized market revenue data forecast to 2020 and company share data for 2013.

- Qualitative analysis of key trends in the facial aesthetics market.

- Information on the competitive landscape and the leading technologies of key players: Allergan, Galderma, Merz Pharma, Ipsen, Anteis, Valeant Pharmaceuticals International, Medytox, LIBP, Laboratoires Teoxane and Hugel.

Reasons to buy

- Develop business strategies by understanding the trends and developments driving the global facial aesthetics market.

- Design and enhance your product development, marketing, and sales strategies.

- Exploit merger and acquisition opportunities by identifying the market players with the most innovative pipelines.

- Develop market-entry and market-expansion strategies.

- Identify the key players best positioned to take advantage of the emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.

- Identify, understand and capitalize emerging blockbusters of the facial aesthetics market landscape.

- Make more informed business decisions from insightful and in-depth analysis of the global facial aesthetics market and the factors shaping it.

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Detailed Report at: http://www.reportsandintelligence.com/breast-cancer-therapeutics-in-asia-pacific-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-market

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes - 

- Disease overview, as well as treatment algorithms and treatment usage patterns

- Market size and forecast for the APAC breast cancer market from 2013 to 2020

- Major marketed products in the APAC region along with a heat map of product performance

- In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis

- Key drivers and restraints that have had and are expected to have a significant impact upon the market

- Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to - 

- Align your product portfolio to the markets with high growth potential

- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth

- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market

- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Web Link: http://www.reportsandintelligence.com/

Frontier Pharma Report: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Epidemiology Forecast to 2020

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Identifying and Commercializing First-in-Class Innovation

Highly Innovative and Diverse Pipeline

GBI Researchs analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets.The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development.

Detailed report at: http://www.reportsandintelligence.com/frontier-pharma-duchenne-muscular-dystrophy-and-becker-muscular-dystrophy-identifying-and-commercializing-first-in-class-innovation-market

This exceptional first-in-class innovation is largely due to the high number of first-in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. The strong presence of first-in-class products in the pipeline therefore creates a distinctly different landscape to the market landscape, which relies on symptomatic treatment glucocorticoids.

Inquire for sample request at: http://www.reportsandintelligence.com/enquire-about-report/245544

Despite a strong focus on personalized treatments that treat the genetic cause of the disease in the DMD/BMD pipeline, innovation is also concentrated on novel molecular targets that alleviate the dystrophic pathology regardless of gene mutations, thereby allowing widespread use in contrast to the mutation-specific treatments. These therapies are expected to be used alongside primary treatment to repair the mutated gene, halt muscle degeneration, and improve life expectancy of patients in the future market.
Strong Alignment of Innovation to Genetics and Disease Processes in Early Pipeline

Analysis also indicates opportunities for some of the first-in-class DMD/BMD targets to be repositioned to other MDs, although this is expected to be challenging given the currently limited understanding of the common molecular processes defected across multiple types of MD.

Numerous Investment Opportunities in Deals Landscape

Strategic consolidation is relatively uncommon in the DMD/BMD market, with 15 licensing agreements and 18 co-development deals between 2006 and April 2015. Supported by findings from the industry-wide analysis, there is a tendency for first-in-class DMD programs to attract higher deal values than non-first-in-class programs, thus highlighting their commercial attractiveness.

With 36 first-in-class products that are currently in development having not yet been involved in a licensing or co-development deal, there are numerous opportunities for in-licensing or co-development in this indication.

Web link: http://www.reportsandintelligence.com/

Asthma – Trends and commercial aspect

Asthma – Trends and commercial aspects 

Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation

Based on deep dive analysis of the asthma market, it can be safely assumed that the asthma pipeline research to be one among the most active processes. There are almost 252 products that are in an active development in all the stages of the clinical research. There has been a significant breakthrough that is observed when innovation is considered. Based on existing market products, the compounds that are witnessing breakthrough are highly diverse in there mode of action.  Drug companies can take this as an opportunity and work on floating products that can offer advantage in various geographies.

As per a research, 50 first-in-class programs are identified in the asthma market. The programs are focused towards targeting 43 first-in-class molecular targets. 

Browse Complete Report With TOC: http://www.reportsandintelligence.com/frontier-pharma-asthma-identifying-and-commercializing-first-in-class-innovation-market

Almost 23% of the products with disclosed molecular targets are expected to witness the results of the latest innovations in the asthma market. These factors will act as very powerful drivers for the market and will lead big pharma companies to take full advantage of the prevailing opportunities in the segment. Despite high clinical trial attrition during research activities, the market study confirms that many of the first-in-class technologies will penetrate the market in the near future. The widespread adoption of these technologies will have a transforming effect in the clinical and commercial domains.

Biologics: a new wave in Asthma Treatment

 Small molecules are currently dominating the asthma market, accounting to approximately 99%.  The current trends in the asthma pipeline includes 64 biologics, adding to almost 24% of the overall in the pipeline products. Small molecules in themselves account to 178 compounds, adding to 66% of the drugs in the pipeline.

The numbers clearly suggest that there is a widespread acceptance, that is, both commercially and clinically to the development of biologics. The trend has an influence over other therapeutic areas such as oncology.  According to a finding, “Xolair (omalizumab), a recombinant humanized anti-IgE monoclonal Antibody (mAb), was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with Inhaled Corticosteroids (ICS).”

Among the targeted therapies, Xolair is also one among the targeted therapy that was greatly successful in treating a specific asthma phenotype. The launch of this therapy had answers to many unmet needs for the treatment of asthma. It is estimated that almost 60% of the people suffering for asthma are allergic, and the use of Xolair can greatly benefit such patients. A very small part of the patient pool suffers from moderate to severe disease and needs to be treated.

Despite limited patient pool, the Xolair drug has managed to achieve a blockbuster status, and this status can be attributed to high annual cost of therapy (ACoT), and innovative drug development that meets the unmet needs. Aforementioned factors contribute to a strong commercial success of Xolair and make them a preferred choice among the suffering populace.    

The success of some isolated yet highly specific biologics are paving way for many such innovative drugs by thee drug developers. The target for highly specific biologics, aimed to meet specific needs might transform the way in which research is now conducted. Targeted drug therapies will benefit a specific patient population and also generate handsome revenue to the drug developers.

Prevailing Investment opportunities:

Based on statistical analysis, it is confirmed that 52 out of 59 first-in-class products are not in the process of licensing or in a co-development deal. Many promising therapies for asthma are in the pipeline and look to be potential therapeutic for asthma treatment. Therefore, successful innovations will be a great investing tool for stake holders and may prove profitable in the long run. The report covers significant strategic implication for biotech companies seeking out-license products and firms with in-licensing products. Both clinical and commercial prospects are dealt in detail to give strategic insights to the stake holders.

Explore more reports on Pharmaceuticals industry at: http://www.reportsandintelligence.com/pharmaceuticals-market-report